• Standard BioTools posted Q2 2026 revenue of $20.1 million, down 7.6% year-over-year.
• Operating loss narrowed 1% to $25.4 million, while GAAP net loss from continuing operations widened 21% to $21.5 million.
• Adjusted EBITDA loss shrank to $2.5 million from $16.1 million a year earlier, a year-over-year improvement of 84%.
• Cash, cash equivalents, restricted cash, short-term and long-term investments climbed to $541.1 million.
• Merger with Treeline Biosciences is progressing toward a stockholder vote, with closing anticipated before year-end 2026; full-year revenue outlook was withdrawn.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804401) on August 05, 2026, and is solely responsible for the information contained therein.